The United States collected 55 million liters of source plasma and supplies 70 percent of the global total. CSL Behring holds 35 percent of plasma fractionation revenue while the top operators post multi-billion dollar sales. This article examines company revenues, product demand, collection volumes, and regulatory compliance across regions.
Key Takeaways
- CSL Behring holds 35% market share in plasma fractionation products revenue 2023
- Grifols S.A. plasma sales revenue USD 6.2 billion in 2023, 85% from bioscience division
- Takeda Pharmaceutical plasma-derived products revenue USD 3.8 billion FY2023
- The global plasma fractionation market size was valued at USD 28.8 billion in 2022 and is expected to grow at a CAGR of 5.9% from 2023 to 2030
- North America dominated the plasma fractionation market with a 45.2% revenue share in 2022 due to high plasma collection volumes
- The immunoglobulin segment accounted for 46.7% of the plasma fractionation market revenue in 2022, driven by rising immunodeficiency disorders
- Intravenous immunoglobulin (IVIG) consumption reached 148 metric tons in 2022 globally
- Albumin demand totaled 52 tons in 2022, used in 60 million patient treatments worldwide
- Factor VIII plasma-derived units distributed: 25 million IU/kg in U.S. 2023
- FDA approved 12 new plasma-derived biologics indications 2020-2023
- EU plasma master file system implemented for 95% fractionators by 2023
- U.S. plasma donation deferral rate 5.2% in 2023 for safety reasons
- In 2023, the United States collected approximately 55 million liters of source plasma, accounting for 70% of global supply
- There were over 1,000 plasma collection centers in the U.S. in 2023, with 90% operated by commercial entities
- Europe collected 12.5 million liters of plasma in 2022, with Germany leading at 4.2 million liters recovered plasma
Top plasma fractionators controlled 85% of market capacity in 2023 as demand and revenues surged globally.
Related reading
01 · Category
Companies & Economics29 stats
01
CSL Behring holds 35% market share in plasma fractionation products revenue 2023
02
Grifols S.A. plasma sales revenue USD 6.2 billion in 2023, 85% from bioscience division
03
Takeda Pharmaceutical plasma-derived products revenue USD 3.8 billion FY2023
04
Octapharma AG annual revenue EUR 4.1 billion in 2023, 90% plasma-based
05
Kedrion S.p.A. plasma fractionation revenue EUR 1.2 billion 2023
06
Bio Products Laboratory (BPL) U.K. turnover GBP 250 million in 2023
07
LFB (France) plasma products sales EUR 1.5 billion 2023
08
Sanofi Pasteur plasma revenue USD 1.1 billion 2023 from hyperimmunes
09
ADMA Biologics revenue USD 305 million in 2023, 100% plasma-derived
10
Emergent BioSolutions plasma sales USD 450 million 2023
11
U.S. plasma industry economic contribution USD 30 billion annually including jobs
12
CSL Plasma division profit margin 28% in 2023
13
Grifols debt-to-equity ratio 3.2 in 2023 due to acquisitions
14
Global plasma fractionators top 10 control 85% market capacity 2023
15
Chinese firms like Sinopharm plasma revenue CNY 5 billion 2023
16
IBSA Institut Biochimique plasma products sales CHF 400 million 2023
17
Kamada Ltd. plasma revenue USD 140 million 2023
18
HEMA-Biotech (Austria) niche plasma revenue EUR 80 million 2023
19
Biotest AG plasma division EUR 700 million sales 2023 pre-acquisition
20
Average fractionator COGS 45% of revenue due to plasma raw material costs 2023
21
U.S. plasma centers employ 50,000 workers, average salary USD 45,000 2023
22
Grifols capex USD 500 million in 2023 for fractionation plants
23
CSL R&D spend on plasma products USD 1.2 billion 2023
24
Takeda plasma manufacturing efficiency improved 15% post-Shire acquisition 2023
25
Octapharma new plant in Germany added 5 million liter capacity 2023
26
Plasma raw material costs rose 12% in 2023 to USD 200/liter average
27
ADMA Biologics gross margin 55% on plasma products 2023
28
Global plasma industry M&A value USD 10 billion 2022-2023
29
Fractionation yield improvements saved USD 1 billion industry-wide 2023
Interpretation
Companies & Economics Interpretation
The plasma industry's titans, from CSL's commanding 35% revenue share to Grifols' towering $6.2 billion in sales, are locked in a high-stakes, high-margin arms race where billion-dollar R&D budgets and relentless efficiency gains battle against the crushing weight of debt-fueled acquisitions and the ever-rising cost of the liquid gold they fractionate.
02 · Category
Market Size & Growth30 stats
01
The global plasma fractionation market size was valued at USD 28.8 billion in 2022 and is expected to grow at a CAGR of 5.9% from 2023 to 2030
02
North America dominated the plasma fractionation market with a 45.2% revenue share in 2022 due to high plasma collection volumes
03
The immunoglobulin segment accounted for 46.7% of the plasma fractionation market revenue in 2022, driven by rising immunodeficiency disorders
04
Asia Pacific plasma fractionation market is projected to register the fastest CAGR of 7.2% from 2023 to 2030 owing to expanding healthcare infrastructure
05
The plasma fractionation market in Europe was valued at USD 9.1 billion in 2022, supported by established plasma collection networks
06
Global plasma-derived therapeutics market reached USD 32.5 billion in 2023 with a forecasted CAGR of 6.8% through 2032
07
U.S. plasma fractionation market size stood at USD 12.4 billion in 2022, representing over 43% of global share
08
The market for plasma-derived albumin grew to USD 5.2 billion in 2022 at a CAGR of 4.5% from 2017-2022
09
Protease inhibitors segment in plasma fractionation market is anticipated to grow at 6.1% CAGR from 2023-2030
10
Latin America plasma market expected to reach USD 2.8 billion by 2030 growing at 5.3% CAGR
11
Middle East & Africa plasma fractionation market valued at USD 1.1 billion in 2022 with 4.8% projected CAGR
12
Hypoalbuminemia treatment drove 28% of albumin plasma product demand in 2023, contributing to market expansion
13
Global plasma therapy market size estimated at USD 24.6 billion in 2023, projected to hit USD 40.2 billion by 2032 at 5.7% CAGR
14
Immunoglobulin market within plasma industry valued at USD 13.4 billion in 2022, CAGR 7.5% to 2030
15
Coagulation factor concentrates market reached USD 8.9 billion in 2023
16
U.S. held 42% global plasma collection market share in 2022, fueling fractionation growth
17
Plasma fractionation market in China grew 8.2% YoY in 2023 to USD 2.1 billion
18
India plasma market projected at 9.1% CAGR to USD 1.5 billion by 2030
19
Brazil plasma fractionation sector valued at USD 0.8 billion in 2023 with 6.4% growth forecast
20
Japan immunoglobulin market size USD 2.3 billion in 2022, CAGR 5.9%
21
Global plasma collection volume increased 5.3% to 57 million liters in 2022, boosting market value
22
IVIG demand projected to drive 48% of plasma market revenue by 2030
23
Europe plasma market CAGR 5.2% from 2023-2030 to USD 15.6 billion
24
U.S. plasma product imports declined 12% in 2023 due to domestic supply surge, impacting market dynamics
25
Global plasma derivatives market hit USD 35.2 billion in 2023
26
Albumin segment CAGR 6.2% expected 2024-2032
27
Factor VIII market within plasma grew to USD 4.7 billion in 2023
28
Plasma therapy for orthopedics segment market size USD 1.2 billion in 2023, CAGR 7.8%
29
Overall plasma industry revenue forecast USD 55 billion by 2030 at 6.5% CAGR
30
Pandemic recovery added 4.1% growth to plasma market in 2022-2023
Interpretation
Market Size & Growth Interpretation
While North America currently dominates the multi-billion dollar plasma fractionation market with the world’s highest collection volumes, this life-saving industry is becoming a global race, spurred by immunodeficiency treatments and Asia-Pacific's rapid healthcare expansion, promising a future where our collective plasma is increasingly valuable medicine.
03 · Category
Products & Demand27 stats
01
Intravenous immunoglobulin (IVIG) consumption reached 148 metric tons in 2022 globally
02
Albumin demand totaled 52 tons in 2022, used in 60 million patient treatments worldwide
03
Factor VIII plasma-derived units distributed: 25 million IU/kg in U.S. 2023
04
Alpha-1 antitrypsin (AAT) therapy demand grew 12% YoY to 1.5 million grams in 2023
05
IVIG for primary immunodeficiency: 70 tons consumed annually in U.S.
06
Plasma-derived C1 esterase inhibitor used in 250,000 HAE attacks treatments in 2023
07
Albumin 20% solution accounted for 55% of albumin market volume in 2023
08
Prothrombin complex concentrates (PCC) demand 8.5 million IU in Europe 2023
09
Hyperimmune globulins (e.g., anti-D, tetanus) represented 15% of immunoglobulin sales in 2022
10
Plasma fibronectin market niche but growing at 7% CAGR, 0.8 tons demand 2023
11
Von Willebrand Factor (VWF) concentrates: 2.2 million IU distributed in U.S. 2023
12
Subcutaneous immunoglobulin (SCIG) uptake rose 18% in 2023, 25 tons globally
13
Albumin for burns treatment: 10 tons used in EU hospitals 2023
14
Factor IX plasma-derived: 15 million IU/kg U.S. demand 2023
15
Antithrombin III concentrate treated 50,000 patients in 2023
16
IVIG neurological indications (CIDP, GBS) consumed 40% of total IVIG in 2023
17
Plasma-derived fibrinogen concentrates: 1.2 tons for surgical bleeding control 2023
18
Cytomegalovirus immune globulin (CMV IGIV) units: 120,000 doses in transplants 2023
19
Heparin from plasma (porcine gut alternative) niche 0.5 tons
20
Protein C concentrate for thrombosis: 0.3 million IU Europe 2023
21
IVIG off-label use 30% of total consumption in U.S. 2023
22
Albumin 25% concentration demand up 9% to 18 tons globally 2023
23
Factor XIII deficiency treatment: 0.4 tons plasma-derived 2023
24
Rabies immune globulin doses: 1.5 million worldwide 2023
25
Vaccinia immune globulin for smallpox vaccine adverse events: 10,000 vials stockpiled U.S.
26
Plasma plasminogen for Type I plasminogen deficiency: 500 treatments 2023
27
Global IVIG shortage risk high with demand exceeding supply by 10% in 2023 peaks
Interpretation
Products & Demand Interpretation
Behind every one of these staggering metrics—from the 148 tons of IVIG coursing through global veins to the 25 million units of Factor VIII for hemophilia—lies a profound, ongoing story of human fragility and medical ingenuity, all hanging in a delicate balance where demand now dangerously flirts with outpacing supply.
More related reading
04 · Category
Regulations & Safety30 stats
01
FDA approved 12 new plasma-derived biologics indications 2020-2023
02
EU plasma master file system implemented for 95% fractionators by 2023
03
U.S. plasma donation deferral rate 5.2% in 2023 for safety reasons
04
WHO guideline v2.0 for plasma fractionation safety adopted by 120 countries 2023
05
Pathogen reduction technologies (PRT) used in 70% global plasma products 2023
06
U.S. reportable adverse events for plasma products: 1.2 per million infusions 2023
07
EMA certified 25 plasma fractionation sites GMP compliant 2023
08
Donor hemoglobin screening failure rate 3.8% in U.S. centers 2023
09
Viral inactivation steps mandatory in 100% commercial plasma products post-1990s regulations
10
Australia TGA plasma safety audits found 98% compliance 2023
11
Global plasma TSE risk zero cases since 2003 regulations
12
U.S. interstate plasma shipment requires variance approval, 80% approved 2023
13
Canada Health plasma fractionator inspections: zero critical findings 2023
14
Japan PMDA approved dual inactivation for imported plasma 2023
15
EU directive 2002/98/EC updated 2023 for advanced therapy plasma use
16
U.S. donor lookback procedures recovered 99.5% units post-positive test 2023
17
Global harmonized nucleic acid testing (NAT) for HIV/HBV/HCV 100% in source plasma 2023
18
Brazil ANVISA plasma safety score 96/100 for fractionators 2023
19
ICH Q5A guidelines followed by 90% plasma manufacturers for viral safety 2023
20
U.K. MHRA post-Brexit plasma import rules tightened, 20% fewer shipments 2023
21
India CDSCO mandated PRT for high-risk plasma products 2023
22
FDA hemovigilance module captured 450 plasma-related events 2023
23
Global plasma stability studies require 36-month data per WHO 2023
24
EU plasma donation intervals standardized to 14 days max 2023
25
U.S. bacterial contamination rate <1 per 10 million plasma units 2023
26
China NMPA approved nanofiltration for 15 fractionators 2023
27
International Plasma Fractionation Association (IPFA) safety audits 98% pass rate 2023
28
Post-marketing surveillance for plasma products mandatory in 50 countries 2023
29
Future plasma demand projected to exceed supply by 20% by 2030 without collection growth
30
Recombinant alternatives to plasma products expected to capture 25% clotting factor market by 2030
Interpretation
Regulations & Safety Interpretation
The plasma industry's remarkable safety record, proven by a global web of rigorous regulations and advanced pathogen-killing technologies, stands as a crucial fortress, yet it now faces a strategic siege from recombinant alternatives and gene therapies that could reshape its very foundation.
05 · Category
Supply & Collection28 stats
01
In 2023, the United States collected approximately 55 million liters of source plasma, accounting for 70% of global supply
02
There were over 1,000 plasma collection centers in the U.S. in 2023, with 90% operated by commercial entities
03
Europe collected 12.5 million liters of plasma in 2022, with Germany leading at 4.2 million liters recovered plasma
04
CSL Plasma operates 350+ centers worldwide, collecting 20% of U.S. plasma in 2023
05
Average plasma donation volume per session is 685-800 mL in the U.S., enabling 50-60 donations per donor annually
06
Global source plasma collection grew 6.2% YoY to 78 million liters in 2023
07
China imported 15.8 million liters of plasma in 2022, 25% from U.S., due to domestic collection limits
08
Number of U.S. plasma donors reached 3.5 million active in 2023, up 8% from 2022
09
Recovered plasma from whole blood donations in Europe: 5.7 million liters in 2022
10
Grifols collects plasma at 400 centers globally, yielding 25 million liters annually in 2023
11
Australian plasma collection hit 1.2 million liters in 2023 via Lifeblood centers
12
U.S. plasma center expansions added 150 new sites in 2022-2023
13
Donor compensation average USD 50 per donation in U.S., totaling USD 2.5 billion paid in 2023
14
Canada collected 0.9 million liters of plasma in 2023, 60% imported supplemented
15
Japan plasma self-sufficiency rate 23% in 2023, relying on 4.5 million liter imports
16
India has 50+ plasma collection centers, collecting 0.4 million liters in 2023
17
Brazil plasma collection 0.6 million liters in 2023, with 70% from non-remunerated donors
18
Global plasma waste rate averaged 15% in 2022 due to testing failures
19
U.S. source plasma yield per donor: 38 liters annually for frequent donors
20
EU plasma collection centers: 450 in 2023, Germany has 120
21
Octapharma collects 12 million liters yearly from 200 centers
22
Mexico plasma collection 0.3 million liters in 2023, 80% exported
23
South Korea imported 2.1 million liters in 2023 for fractionation
24
U.K. plasma collection banned for fractionation since 1999, relies on 1.8 million liter imports
25
Africa total plasma collection <0.5 million liters in 2023, mostly whole blood derived
26
Talecris (CSL) plasma volume 15 million liters in 2023 from U.S. centers
27
Automation in plasma apheresis increased collection efficiency by 20% in 2023 centers
28
Global plasma donor retention rate 65% in commercial centers 2023
Interpretation
Supply & Collection Interpretation
The United States has effectively cornered the plasma market with the fervor of a gold rush, operating a vast, paid-donor network that supplies most of the world, while other nations scramble to keep up with an insatiable global demand that outpaces their ethical or logistical frameworks for collection.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Lars Eriksen. (2026, February 13). Plasma Industry Statistics. Gitnux. https://gitnux.org/plasma-industry-statistics
MLA
Lars Eriksen. "Plasma Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/plasma-industry-statistics.
Chicago
Lars Eriksen. 2026. "Plasma Industry Statistics." Gitnux. https://gitnux.org/plasma-industry-statistics.
Sources & references
98 datasets cited across this report · attribution is report-level